From Morgans,
Column 1 Column 2 Column 3 Column 4 Column 5 0 26/02/2020 ResApp Health RAP SPEC BUY No surprises given quarterly reporting. Focus will remain on commentary regarding first commercialisation deals (size/pricing/structure) in Europe and Australia followed by US post FDA children’s approval which we expect any day.
https://www.morgans.com.au/research-and-markets/reporting-calendar
GLTAH.
From Morgans, 26/02/2020| ResApp Health| RAP| SPEC BUY| No...
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #